<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.02.12.21251294</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Epidemiology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Seroprevalence of anti-SARS-CoV-2 IgG antibodies among truck drivers and assistants in Kenya</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kagucia</surname><given-names>E Wangeci</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x0023;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gitonga</surname><given-names>John N</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kalu</surname><given-names>Catherine</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ochomo</surname><given-names>Eric</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ochieng</surname><given-names>Benard</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kuya</surname><given-names>Nickline</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Karani</surname><given-names>Angela</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nyagwange</surname><given-names>James</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Karia</surname><given-names>Boniface</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mugo</surname><given-names>Daisy</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Karanja</surname><given-names>Henry K</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tuju</surname><given-names>James</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mutiso</surname><given-names>Agnes</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Maroko</surname><given-names>Hosea</given-names></name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Okubi</surname><given-names>Lucy</given-names></name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Maitha</surname><given-names>Eric</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ajuck</surname><given-names>Hossan</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bogita</surname><given-names>Mary</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mudindi</surname><given-names>Richmond</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mukabi</surname><given-names>David</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Moracha</surname><given-names>Wycliffe</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bulimu</surname><given-names>David</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Andanje</surname><given-names>Nelson</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shiraku</surname><given-names>Evans</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Okuku</surname><given-names>Rosemary</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ogutu</surname><given-names>Monicah</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Aman</surname><given-names>Rashid</given-names></name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mwangangi</surname><given-names>Mercy</given-names></name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Amoth</surname><given-names>Patrick</given-names></name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kasera</surname><given-names>Kadondi</given-names></name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ng&#x2019;ang&#x2019;a</surname><given-names>Wangari</given-names></name>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mariga</surname><given-names>Rodgers</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Munabi</surname><given-names>Tobias</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ramadhan</surname><given-names>Susan M</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mwikali</surname><given-names>Janet</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nasike</surname><given-names>Rose</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Andera</surname><given-names>Cornelius</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nechesa</surname><given-names>Roselyne</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kiplagat</surname><given-names>Benson K</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Omengo</surname><given-names>Julius</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Oteba</surname><given-names>Simon</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mwangi</surname><given-names>Arthur</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mkanyi</surname><given-names>Dorcas</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Karisa</surname><given-names>George</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Migosi</surname><given-names>Judith K</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Msili</surname><given-names>Patrick</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mwambire</surname><given-names>Samson</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Boniface</surname><given-names>Anthony M</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nyaguara</surname><given-names>Amek</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Voller</surname><given-names>Shirine</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Otiende</surname><given-names>Mark</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bottomley</surname><given-names>Christian</given-names></name>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Agoti</surname><given-names>Charles N</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ochola-Oyier</surname><given-names>Lynette I</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2556-9407</contrib-id>
<name><surname>Adetifa</surname><given-names>Ifedayo M O</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Etyang</surname><given-names>Anthony O</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gallagher</surname><given-names>Katherine E</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Uyoga</surname><given-names>Sophie</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Barasa</surname><given-names>Edwine</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bejon</surname><given-names>Philip</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a9">9</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tsofa</surname><given-names>Benjamin</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Agweyu</surname><given-names>Ambrose</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Warimwe</surname><given-names>George M</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a9">9</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Scott</surname><given-names>J Anthony G</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a8">8</xref>
<xref ref-type="aff" rid="a9">9</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>KEMRI-Wellcome Trust Research Programme</institution>, Kilifi, <country>Kenya</country></aff>
<aff id="a2"><label>2</label><institution>KEMRI Centre for Global Health Research (CGHR)</institution>, Kisumu, <country>Kenya</country></aff>
<aff id="a3"><label>3</label><institution>KEMRI Centre for Infectious and Parasitic Diseases Control Research</institution>, Alupe, <country>Kenya</country></aff>
<aff id="a4"><label>4</label><institution>Department of Health</institution>, Kilifi County, <country>Kenya</country></aff>
<aff id="a5"><label>5</label><institution>Department of Health</institution>, Busia County, <country>Kenya</country></aff>
<aff id="a6"><label>6</label><institution>Ministry of Health, Government of Kenya</institution>, Nairobi, <country>Kenya</country></aff>
<aff id="a7"><label>7</label><institution>Presidential Policy and Strategy Unit, The Presidency</institution>, Government of Kenya</aff>
<aff id="a8"><label>8</label><institution>Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine</institution>, <country>UK</country></aff>
<aff id="a9"><label>9</label><institution>Nuffield Department of Medicine, Oxford University</institution>, <country>UK</country></aff>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>&#x002A;</label><p>These authors contributed equally to this work</p></fn>
<corresp id="cor1"><label>&#x0023;</label><bold>Corresponding Author</bold> E. Wangeci Kagucia, KEMRI-Wellcome Trust Research Programme, Hospital Road, P. O. Box 230-80108, Kilifi, Kenya, <email>ekagucia@kemri-wellcome.org</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.02.12.21251294</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>2</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>12</day>
<month>2</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>2</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="21251294.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>In October 2020, anti-SARS-CoV-2 IgG seroprevalence among truck drivers and their assistants (TDA) in Kenya was 42.3&#x0025;, higher than among other key populations. TDA transport essential supplies during the COVID-19 pandemic, placing them at increased risk of being infected and of transmitting SARS-CoV-2 infection over a wide geographical area.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Truck drivers</kwd>
<kwd>lorry drivers</kwd>
<kwd>frontline workers</kwd>
<kwd>essential workers</kwd>
<kwd>SARS-CoV-2</kwd>
<kwd>COVID-19</kwd>
<kwd>serosurveillance</kwd>
<kwd>seroprevalence</kwd>
<kwd>antibodies</kwd>
<kwd>Kenya</kwd>
<kwd>sub-Saharan Africa</kwd>
</kwd-group>
<counts>
<page-count count="11"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>RA, MM, KK and PA are from the Ministry of Health, Government of Kenya. All other authors declare no competing interests.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>This project was funded by the Wellcome Trust (grants 220991/Z/20/Z and 203077/Z/16/Z), the Bill and Melinda Gates Foundation (INV-017547), and the Foreign Commonwealth and Development Office (FCDO) through the East Africa Research Fund (EARF/ITT/039) and is part of an integrated programme of SARS-CoV-2 serosurveillance in Kenya led by KEMRI-Wellcome Trust Research Programme. The views expressed in this publication are those of the authors and not necessarily those of the funding agencies.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>Kenya Medical Research Institute Scientific and Ethics Review Committee</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Serosurveillance for antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be used to estimate the cumulative incidence of SARS-CoV-2 infection. This is of particular interest among frontline workers, such as truck drivers and their assistants (TDA), who are exempted from coronavirus disease 2019 (COVID-19) restrictions such as curfews and lockdowns.</p>
<p>Shortly after the first locally detected SARS-CoV-2 infection in March 2020, the Government of Kenya instituted containment measures, including travel restrictions[<xref ref-type="bibr" rid="c1">1</xref>]. Freight transportation was excluded from travel restrictions as TDA were deemed essential workers [<xref ref-type="bibr" rid="c2">2</xref>]. In May 2020 the Kenya Ministry of Health implemented mandatory bimonthly SARS-CoV-2 nucleic acid testing (NAT) for TDA, in line with East African Community (EAC) guidelines[<xref ref-type="bibr" rid="c3">3</xref>, <xref ref-type="bibr" rid="c4">4</xref>]. Though NAT data can be used to estimate the cumulative incidence of SARS-CoV-2 infection[<xref ref-type="bibr" rid="c5">5</xref>], accurate estimates are dependent on the availability of reliable model parameter values.</p>
<p>There are currently no estimates of SARS-CoV-2 antibody seroprevalence among TDA globally. Due to the nature of their work, TDA interact with a wide variety of social and professional contacts over a large geographical area, putting them at increased risk of SARS-CoV-2 infection. We undertook a serosurvey to estimate the prevalence of SARS-CoV-2 antibodies among TDA in Kenya.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<sec id="s2a">
<title>Study design and participants</title>
<p>A cross-sectional serosurvey was conducted at three sites, one in Kilifi County in South-Eastern Kenya, and two in Busia County in Western Kenya (<bold>Supplementary Figure 1</bold>). In Kilifi County, TDA transporting salt domestically and to East African countries (e.g., Uganda, Rwanda and Burundi) were engaged at salt harvesting companies located in Gongoni area, Magarini Sub-County, whilst waiting for salt to be loaded to their trucks. In Busia County, TDA were engaged at One Stop Border Posts (OSBPs) in two border towns, Busia and Malaba as they presented for nasopharyngeal and oropharyngeal (NP/OP) sample collection for NAT as mandated by the Kenyan government. TDA at Busia OSBP and Malaba OSBP typically transport freight between Mombasa on the Indian Ocean Coast, and countries in East Africa (<bold>Supplementary Figure 2</bold>). Busia town is larger and more populous than Malaba[<xref ref-type="bibr" rid="c6">6</xref>] yet a higher number of trucks transit through Malaba[<xref ref-type="bibr" rid="c7">7</xref>].</p>
<p>TDA were eligible if they were aged &#x2265;18 years without a medical contraindication for blood sample collection. Participation was voluntary and verbal consent was sought prior to blood sample collection. Serosurveillance was conducted as a public health activity requested by the Kenya Ministry of Health and ethical approval for publication of these data was obtained from the Kenya Medical Research Institute Scientific and Ethics Review Unit (KEMRI/SERU/CGMR-C/203/4085).</p>
</sec>
<sec id="s2b">
<title>Data and sample collection</title>
<p>Sociodemographic and clinical data, including age, sex, nationality, residence, temperature and symptoms of illness within the previous two weeks, were collected by county public health staff (CPHS) and recorded on governmental COVID-19 surveillance forms (<bold>Supplementary Forms 1 and 2</bold>). Venous blood samples were collected in heparinized tubes using standard blood sample collection procedures, labelled with the same anonymous unique identifier as NP/OP samples, then stored in an insulated cool box prior to transportation to the laboratory for processing. NP/OP NAT results, linked using the anonymous unique identifiers, were obtained from testing laboratories. Data with personal identifiers were retained only by CPHS.</p>
</sec>
<sec id="s2c">
<title>Laboratory testing</title>
<p>Plasma was extracted from blood samples using standard techniques and stored at &#x2212;80&#x00B0;C prior to antibody testing. Thawed plasma samples were tested for anti-SARS-CoV-2 IgG using a locally-validated whole spike enzyme-linked immunosorbent assay (ELISA) with 93&#x0025; sensitivity and 99&#x0025; specificity, as described previously [<xref ref-type="bibr" rid="c8">8</xref>, <xref ref-type="bibr" rid="c9">9</xref>]. Spike ELISA positivity was defined as a ratio of sample optical density (OD) over negative control OD &#x003E; 2. NP/OP NAT results are routinely provided to TDA by CPHS. Serology results were also provided to TDA by CPHS.</p>
</sec>
<sec id="s2d">
<title>Statistical analysis</title>
<p>At least 700 samples were required to estimate seroprevalence as low as 2&#x0025; within a 1&#x0025; margin of error. Age was categorized into 10-year strata. Seroprevalence was estimated as a simple proportion of the number of anti-SARS-CoV-2 IgG positive samples (OD ratio &#x003E;2) divided by all samples. Associated exact binomial 95&#x0025; confidence intervals (CI) were calculated for all seroprevalence estimates. Bayesian adjustment for assay sensitivity and specificity was performed as previously described [<xref ref-type="bibr" rid="c9">9</xref>]. Associations between seropositivity and sociodemographic/clinical characteristics were tested using chi-squared or Fisher&#x2019;s exact tests. Bayesian test-performance-adjusted seroprevalence estimates were calculated in R (version 3.6.1) with RStan. All other analyses were performed using Stata (version 15.1).</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<p>The serosurvey was conducted in Magarini between September 30 and October 23, 2020 and in Busia County on October 13-15, 2020. In total, 830 TDA (Busia OSBP n= 365; Magarini n= 101; Malaba OSBP n= 364) provided a blood sample, representing 52.4&#x0025; of TDA approached (<bold>Supplementary Figure 3</bold>). Of the 830 samples, 91.1&#x0025; were collected between October 13-15 (<bold>Supplementary Figure 4</bold>). The median age of sampled TDA was 40 years (IQR 34-48 years) and 668 (80.5&#x0025;) were Kenyan. Only 3 (0.4&#x0025;) of the TDA were female (<bold><xref rid="tbl1" ref-type="table">Table 1</xref></bold>). Among Kenyan TDA, reported county of residence included 31 of the country&#x2019;s 47 counties. The most common counties of residence were Mombasa, Uasin Gishu and Nakuru (<bold>Supplementary Table 1</bold>). Driver vs assistant status was not recorded but, on the basis of truck driver licensure age requirements, at least 53 (6.4&#x0025;) were assistants.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><p>Crude and test-performance adjusted anti-SARS-CoV-2 IgG seroprevalence among TDA in Kenya, September 30 to October 23, 2020</p></caption>
<graphic xlink:href="21251294v1_tbl1.tif"/>
</table-wrap>
<p>Of 785 TDA with available NAT results, 58 (7.4&#x0025;) were positive for SARS-CoV-2 (<bold><xref rid="tbl1" ref-type="table">Table 1</xref></bold>) with NAT positivity being significantly higher in Magarini (25 of 93; 26.9&#x0025;) compared to Busia OSBP (15 of 348; 4.3&#x0025;) and Malaba OSBP (18 of 344; 5.2&#x0025;; p &#x003C;0.001<bold>; Supplementary Table 2</bold>). None of the 830 TDA reported current or previous symptoms of illness. Only one individual had a temperature of 37.5&#x00B0;C or higher (<bold>Supplementary Table 2</bold>) and the NAT result was negative in that one case.</p>
<p>Crude overall anti-SARS-CoV-2 IgG seroprevalence among sampled TDA was 39.6&#x0025; (95&#x0025; confidence interval 36.3-43.1). After adjustment for assay sensitivity and specificity it was 42.3&#x0025; (95&#x0025; credible interval 38.4-46.3). Seroprevalence was highest in those &#x003C;30 years of age and lowest among those aged &#x2265;50 years. All three female TDA were seropositive for anti-SARS-CoV-2 IgG. Seroprevalence was 39.6&#x0025; (35.0-43.9) among TDA negative for SARS-CoV-2 by NAT and 59.0&#x0025; (46.0-72.1) among those with a positive SARS-CoV-2 NAT result. Seroprevalence among Kenyan TDA was comparable to that of other nationalities. By site, seroprevalence was highest at Busia OSBP and lowest at Malaba OSBP. Crude heterogeneity tests and uncertainty intervals for antibody test-adjusted estimates suggested no significant association between seroprevalence and age and significant differences in seroprevalence by site (<bold>Table 1</bold> and <bold>Supplementary Table 3</bold>). Stratum-specific adjusted seroprevalence estimates were generally higher than crude estimates (<bold><xref rid="tbl1" ref-type="table">Table 1</xref></bold>).</p>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>We estimate that approximately 4 in 10 TDA in Kenya had been infected with SARS-CoV-2 by late October 2020, as the country experienced the initial stages of a second pandemic wave [<xref ref-type="bibr" rid="c10">10</xref>]. This study is notable for being the first to report SARS-CoV-2 seroprevalence among TDA.</p>
<p>Anti-SARS-CoV-2 IgG seroprevalence among TDA was more than 4-fold higher compared to average seroprevalence among Kenyan blood donors by September 2020[<xref ref-type="bibr" rid="c11">11</xref>] and 2-fold higher compared to average seroprevalence in HCW across five Kenyan health facilities by October 2020 [<xref ref-type="bibr" rid="c12">12</xref>]. As such, the findings suggest exposure to SARS-CoV-2 among TDA in Kenya was higher than in the general population and among other frontline workers.</p>
<p>Some studies found seroprevalence of SARS-CoV-2 antibodies among HCW similar to that among TDA in Kenya: 45&#x0025; in London[<xref ref-type="bibr" rid="c13">13</xref>]; 44&#x0025; in Indiana[<xref ref-type="bibr" rid="c14">14</xref>]; and 45&#x0025; in Ibadan, Nigeria[<xref ref-type="bibr" rid="c15">15</xref>]. However, meta-analyses of studies globally estimated SARS-CoV-2 antibody prevalence among HCWs at 7&#x0025; by July 2020 [<xref ref-type="bibr" rid="c16">16</xref>] and 9&#x0025; by August 2020[<xref ref-type="bibr" rid="c17">17</xref>]. Taken together, these data suggest exposure to SARS-CoV-2 among TDA was higher than among HCWs in most settings.</p>
<p>To date, few studies have assessed SARS-CoV-2 antibody prevalence in non-healthcare frontline workers. Seroprevalence was 38&#x0025; seroprevalence among male migrant supermarket workers in Kuwait in May to June 2020 (during a peak in daily COVID-19 cases)[<xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c18">18</xref>]. Elsewhere, however, seroprevalence among non-HCWs has been much lower. SARS-CoV-2 antibody seroprevalence was 1&#x0025; in Croatia, just prior to easing of nationwide COVID-19 restrictions in late April 2020[<xref ref-type="bibr" rid="c19">19</xref>]; 9-11&#x0025; in France following the initial pandemic wave[<xref ref-type="bibr" rid="c20">20</xref>]; 20&#x0025; in Chicago, Illinois, US during the summer of 2020 following easing of COVID-19 restrictions[<xref ref-type="bibr" rid="c21">21</xref>]; and 19-22&#x0025; in Iran following the initial pandemic wave[<xref ref-type="bibr" rid="c22">22</xref>].</p>
<p>This study provides some insights into SARS-CoV-2 epidemiology among TDA. None of the TDA with a positive NAT result reported symptoms within two weeks of testing and no instances of pyrexia were identified among them. This suggests a preponderance of asymptomatic COVID-19 among TDA. Although data on symptoms among TDA may have been subject to reporting bias, 93&#x0025; of SARS-CoV-2 infections confirmed in Kenya by October 23, 2020 were asymptomatic[<xref ref-type="bibr" rid="c23">23</xref>]. The similarity in anti-SARS-CoV-2 antibody seropositivity among Kenyan and non-Kenyan TDA indicates predominantly occupation-related exposure to SARS-CoV-2. That seroprevalence differed by sampling site suggests some heterogeneity in risk of exposure.</p>
<p>Despite sampling at three different sites, we cannot be sure that the sample included are representative of all TDA in Kenya, or even those transiting through these sites. Participation in the serosurvey was voluntary, only half of those approached agreed to be sampled, and sociodemographic data for the target population are not available, limiting our ability to assess recruitment bias. However, data on county of residence for Kenyan TDA indicates representation from most counties. Seroprevalence estimates did not account for clustering by site or by driver-assistant pairs. The use of antibodies to estimate cumulative incidence of SARS-CoV-2 infection assumes universal seroconversion, minimal mortality and antibody persistence. If these assumptions are incorrect &#x2013; for example, there is evidence suggestive of antibody waning[<xref ref-type="bibr" rid="c24">24</xref>&#x2013;<xref ref-type="bibr" rid="c26">26</xref>] &#x2013; the cumulative incidence of infection would be underestimated. To minimize bias due to assay sensitivity and specificity, adjusted seroprevalence estimates were calculated.</p>
<p>These findings indicate substantial occupational risk for SARS-CoV-2 infection in TDA, despite prevention measures. In turn, infected TDA can transmit SARS-CoV-2 over a large geographical area. Although this study did not assess the contribution of TDA to SARS-CoV-2 transmission, TDA have been previously associated with spatial spread of emerging infections[<xref ref-type="bibr" rid="c27">27</xref>&#x2013;<xref ref-type="bibr" rid="c30">30</xref>]. As TDA will continue to play an essential role during the COVID-19 pandemic, heightened promotion of existing COVID-19 prevention measures is needed, as is consideration of prioritization of TDA for COVID-19 vaccines with transmission-blocking potential. Nevertheless, supply chains are essential to sustain daily life and for the COVID-19 response. It remains a challenge how to best balance the essential role of TDA with pandemic control.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material>
<label>Supplement</label>
<media xlink:href="supplements/251294_file02.pdf" />
</supplementary-material>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>De-identified data may be requested through the KEMRI-Wellcome Trust Research Programme Data Governance Committee</p>
</sec>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>COVID-19</term>
<def><p>Coronavirus disease 2019</p></def>
</def-item>
<def-item>
<term>CPHS</term>
<def><p>County public health staff</p></def>
</def-item>
<def-item>
<term>ELISA</term>
<def><p>Enzyme-linked immunosorbent assay</p></def>
</def-item>
<def-item>
<term>HCW</term>
<def><p>Healthcare workers</p></def>
</def-item>
<def-item>
<term>NAT</term>
<def><p>Nucleic acid test/ testing</p></def>
</def-item>
<def-item>
<term>NP/OP</term>
<def><p>Nasopharyngeal/ oropharyngeal</p></def>
</def-item>
<def-item>
<term>OD</term>
<def><p>Optical density</p></def>
</def-item>
<def-item>
<term>OSBP</term>
<def><p>One Stop Border Post</p></def>
</def-item>
<def-item>
<term>SARS-CoV-2</term>
<def><p>Severe acute respiratory syndrome coronavirus 2</p></def>
</def-item>
<def-item>
<term>TDA</term>
<def><p>Truck drivers and assistants</p></def>
</def-item>
</def-list>
</glossary>
<sec id="s5">
<title>Funding</title>
<p>This project was funded by the Wellcome Trust (grants 220991/Z/20/Z and 203077/Z/16/Z), the Bill and Melinda Gates Foundation (INV-017547), and the Foreign Commonwealth and Development Office (FCDO) through the East Africa Research Fund (EARF/ITT/039) and is part of an integrated programme of SARS-CoV-2 serosurveillance in Kenya led by KEMRI-Wellcome Trust Research Programme. The views expressed in this publication are those of the authors and not necessarily those of the funding agencies.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We thank the truck drivers and assistants for their participation. We thank the Busia Transporters Chairman for support in engaging truck drivers and assistants. We thank the Busia and Kilifi County Health Management Teams (CHMTs), Busia Port Health, Malaba Port Health, and Gongoni area salt companies for their support of this activity, including training support by Busia and Kilifi CHMT members. We thank the Deputy Director, KEMRI Centre for Global Health Research and Deputy Director, KEMRI Centre for Infectious and Parasitic Diseases Control Research for collaborative agreements to support field and laboratory work. We thank the KEMRI-Wellcome Trust Pneumococcal Conjugate Vaccine Impact Study (PCVIS) field staff for supporting sample collection training and data entry. We thank F. Krammer for providing the plasmids used to generate the spike protein used in this work. Development of SARS-CoV-2 reagents was partially supported by the NIAID Centres of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C. This paper has been published with the permission of the Director, Kenya Medical Research Institute.</p>
<p>AA is funded by a DFID/MRC/NIHR/Wellcome Trust Joint Global Health Trials Award (MR/R006083/1), JAGS is funded by a Wellcome Trust Senior Research Fellowship (214320) and the NIHR Health Protection Research Unit in Immunisation, IMOA is funded by the United Kingdom&#x2019;s Medical Research Council and Department for International Development through an African Research Leader Fellowship (MR/S005293/1) and by the NIHR-MPRU at UCL (grant 2268427 LSHTM). GMW is supported by a fellowship from the Oak Foundation. CNA is funded by the DELTAS Africa Initiative [DEL-15-003], and the Foreign, Commonwealth and Development Office and Wellcome (220985/Z/20/Z). SU is funded by DELTAS Africa Initiative [DEL-15-003], LIO-O is funded by a Wellcome Trust Intermediate Fellowship (107568/Z/15/Z).</p>
<p><italic>This research was funded in whole or in part by the Wellcome Trust (grants 220991/Z/20/Z and 203077/Z/16/Z)</italic>. <bold><italic>For the purpose of Open Access, the author has applied a CC-BY public copyright licence to any author accepted manuscript version arising from this submission</italic></bold>.</p>
</ack>
<sec id="s6">
<title>Potential conflicts of interest</title>
<p>RA, MM, KK and PA are from the Ministry of Health, Government of Kenya. All other authors declare no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="website"><collab>Ministry of Health GoK</collab>. <source>Press statement on the update of coronavirus in the country and response measures</source>. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.health.go.ke/wp-content/uploads/2020/03/Coronavirus-Press-Statement-March-17-2020.pdf">https://www.health.go.ke/wp-content/uploads/2020/03/Coronavirus-Press-Statement-March-17-2020.pdf</ext-link>. Accessed <date-in-citation content-type="access-date">December 21</date-in-citation>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="website"><collab>EAC Secretariat</collab>. <source>EAC administrative guidelines to facilitate movement of good and services during the COVID-19 pandemic</source>. Available at: <ext-link ext-link-type="uri" xlink:href="http://repository.eac.int/handle/11671/2058">http://repository.eac.int/handle/11671/2058</ext-link>. Accessed <date-in-citation content-type="access-date">December 21</date-in-citation>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="website"><collab>Ministry of Health GoK</collab>. <source>Update of coronavirus in the country and response measures, as at 7th May, 2020</source>. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.health.go.ke/wp-content/uploads/2020/05/CamScanner-05-07-2020-16.32.06.pdf">https://www.health.go.ke/wp-content/uploads/2020/05/CamScanner-05-07-2020-16.32.06.pdf</ext-link>. Accessed <date-in-citation content-type="access-date">December 21</date-in-citation>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="website"><collab>Ministry of Health GoK</collab>. <source>Protocol for control of COVID-19 at ground crossings and along the transport corridors</source>. Available at: <ext-link ext-link-type="uri" xlink:href="https://admin-kenya.tradeportal.org/media/Truckers%20Protocol.pdf">https://admin-kenya.tradeportal.org/media/Truckers&#x0025;20Protocol.pdf</ext-link>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Reese</surname> <given-names>H</given-names></string-name>, <string-name><surname>Iuliano</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Patel</surname> <given-names>NN</given-names></string-name>, <etal>et al.</etal> <article-title>Estimated incidence of COVID-19 illness and hospitalization - United States, February-September, 2020</article-title>. <source>Clin Infect Dis</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="other"><collab>Busia County Government</collab>. <source>County Integrated Development Plan 2018-2022</source>, <year>2017</year>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="other"><string-name><surname>Fitzmaurice</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hartmann</surname> <given-names>O.</given-names></string-name> <source>Border crossing monitoring along the Northern Corridor: The International Bank for Reconstruction and Development/ The World Bank</source>, <year>2013</year>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Amanat</surname> <given-names>F</given-names></string-name>, <string-name><surname>Stadlbauer</surname> <given-names>D</given-names></string-name>, <string-name><surname>Strohmeier</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>A serological assay to detect SARS-CoV-2 seroconversion in humans</article-title>. <source>Nat Med</source> <year>2020</year>; <volume>26</volume>(<issue>7</issue>): <fpage>1033</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Uyoga</surname> <given-names>S</given-names></string-name>, <string-name><surname>Adetifa</surname> <given-names>IMO</given-names></string-name>, <string-name><surname>Karanja</surname> <given-names>HK</given-names></string-name>, <etal>et al.</etal> <article-title>Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors</article-title>. <source>Science</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="website"><collab>Johns Hopkins University Center for Systems Science and Engineering</collab>. <source>COVID-19 Dashboard</source>. Available at: <ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html">https://coronavirus.jhu.edu/map.html</ext-link>. Accessed <date-in-citation content-type="access-date">December 20</date-in-citation>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="other"><string-name><surname>Adetifa</surname> <given-names>I</given-names></string-name>, <string-name><surname>Uyoga</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gitonga</surname> <given-names>JN</given-names></string-name>, <etal>et al.</etal> <article-title>Temporal trends of SARS-CoV-2 seroprevalence in transfusion blood donors during the first wave of the COVID-19 epidemic in Kenya</article-title>. <source>medRxiv</source> Submitted.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="other"><string-name><surname>Etyang</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lucinde</surname> <given-names>R</given-names></string-name>, <string-name><surname>Weru</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Seroprevalence of antibodies to SARS-CoV-2 among health care workers in Kenya</article-title>. <source>medRxiv</source> Submitted.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Houlihan</surname> <given-names>CF</given-names></string-name>, <string-name><surname>Vora</surname> <given-names>N</given-names></string-name>, <string-name><surname>Byrne</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers</article-title>. <source>Lancet</source> <year>2020</year>; <volume>396</volume>(<issue>10246</issue>): <fpage>e6</fpage>&#x2013;<lpage>e7</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Hains</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Schwaderer</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Carroll</surname> <given-names>AE</given-names></string-name>, <etal>et al.</etal> <article-title>Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit</article-title>. <source>Jama</source> <year>2020</year>; <volume>323</volume>(<issue>23</issue>): <fpage>2424</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Olayanju</surname> <given-names>O</given-names></string-name>, <string-name><surname>Bamidele</surname> <given-names>O</given-names></string-name>, <string-name><surname>Edem</surname> <given-names>F</given-names></string-name>, <etal>et al.</etal> <article-title>SARS-CoV-2 Seropositivity in Asymptomatic Frontline Health Workers in Ibadan, Nigeria</article-title>. <source>Am J Trop Med Hyg</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>G&#x00F3;mez-Ochoa</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Franco</surname> <given-names>OH</given-names></string-name>, <string-name><surname>Rojas</surname> <given-names>LZ</given-names></string-name>, <etal>et al.</etal> <article-title>COVID-19 in Health-Care Workers: A Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes</article-title>. <source>Am J Epidemiol</source> <year>2021</year>; <volume>190</volume>(<issue>1</issue>): <fpage>161</fpage>&#x2013;<lpage>75</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Galanis</surname> <given-names>P</given-names></string-name>, <string-name><surname>Vraka</surname> <given-names>I</given-names></string-name>, <string-name><surname>Fragkou</surname> <given-names>D</given-names></string-name>, <string-name><surname>Bilali</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kaitelidou</surname> <given-names>D.</given-names></string-name> <article-title>Seroprevalence of SARS-CoV-2 antibodies and associated factors in health care workers: a systematic review and meta-analysis</article-title>. <source>J Hosp Infect</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Alali</surname> <given-names>WQ</given-names></string-name>, <string-name><surname>Bastaki</surname> <given-names>H</given-names></string-name>, <string-name><surname>Longenecker</surname> <given-names>JC</given-names></string-name>, <etal>et al.</etal> <article-title>Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait</article-title>. <source>J Travel Med</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Jerkovi&#x0107;</surname> <given-names>I</given-names></string-name>, <string-name><surname>Ljubi&#x0107;</surname> <given-names>T</given-names></string-name>, <string-name><surname>Ba&#x0161;i&#x0107;</surname> <given-names>&#x017D;</given-names></string-name>, <etal>et al.</etal> <article-title>SARS-CoV-2 Antibody Seroprevalence in Industry Workers in Split-Dalmatia and &#x0161;ibenik-Knin County, Croatia</article-title>. <source>J Occup Environ Med</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Anna</surname> <given-names>F</given-names></string-name>, <string-name><surname>Goyard</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lalanne</surname> <given-names>AI</given-names></string-name>, <etal>et al.</etal> <article-title>High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris</article-title>. <source>Eur J Immunol</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Demonbreun</surname> <given-names>AR</given-names></string-name>, <string-name><surname>McDade</surname> <given-names>TW</given-names></string-name>, <string-name><surname>Pesce</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>Patterns and persistence of SARS-CoV-2 IgG antibodies in a US metropolitan site</article-title>. <source>medRxiv</source> <year>2020</year>: <fpage>2020.11.17.20233452</fpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Poustchi</surname> <given-names>H</given-names></string-name>, <string-name><surname>Darvishian</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mohammadi</surname> <given-names>Z</given-names></string-name>, <etal>et al.</etal> <article-title>SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study</article-title>. <source>Lancet Infect Dis</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="other"><collab>Ministry of Health GoK</collab>. <source>COVID-19 outbreak in Kenya: Daily situation report - 220</source> <day>23</day> <month>October</month> <year>2020</year>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Long</surname> <given-names>QX</given-names></string-name>, <string-name><surname>Tang</surname> <given-names>XJ</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>QL</given-names></string-name>, <etal>et al.</etal> <article-title>Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections</article-title>. <source>Nat Med</source> <year>2020</year>; <volume>26</volume>(<issue>8</issue>): <fpage>1200</fpage>&#x2013;<lpage>4</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Ibarrondo</surname> <given-names>FJ</given-names></string-name>, <string-name><surname>Fulcher</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Goodman-Meza</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title>Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19</article-title>. <source>N Engl J Med</source> <year>2020</year>; <volume>383</volume>(<issue>11</issue>): <fpage>1085</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Self</surname> <given-names>WH</given-names></string-name>, <string-name><surname>Tenforde</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Stubblefield</surname> <given-names>WB</given-names></string-name>, <etal>et al.</etal> <article-title>Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020</article-title>. <source>MMWR Morb Mortal Wkly Rep</source> <year>2020</year>; <volume>69</volume>(<issue>47</issue>): <fpage>1762</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Bwayo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Plummer</surname> <given-names>F</given-names></string-name>, <string-name><surname>Omari</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Human immunodeficiency virus infection in long-distance truck drivers in east Africa</article-title>. <source>Arch Intern Med</source> <year>1994</year>; <volume>154</volume>(<issue>12</issue>): <fpage>1391</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Delany-Moretlwe</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bello</surname> <given-names>B</given-names></string-name>, <string-name><surname>Kinross</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title>HIV prevalence and risk in long-distance truck drivers in South Africa: a national cross-sectional survey</article-title>. <source>Int J STD AIDS</source> <year>2014</year>; <volume>25</volume>(<issue>6</issue>): <fpage>428</fpage>&#x2013;<lpage>38</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Mosoko</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Macauley</surname> <given-names>IB</given-names></string-name>, <string-name><surname>Zoungkanyi</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Bella</surname> <given-names>A</given-names></string-name>, <string-name><surname>Koulla-Shiro</surname> <given-names>S.</given-names></string-name> <article-title>Human immunodeficiency virus infection and associated factors among specific population subgroups in Cameroon</article-title>. <source>AIDS Behav</source> <year>2009</year>; <volume>13</volume>(<issue>2</issue>): <fpage>277</fpage>&#x2013;<lpage>87</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Bot&#x00E3;o</surname> <given-names>C</given-names></string-name>, <string-name><surname>Horth</surname> <given-names>RZ</given-names></string-name>, <string-name><surname>Frank</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal> <article-title>Prevalence of HIV and Associated Risk Factors Among Long Distance Truck Drivers in Inchope, Mozambique, 2012</article-title>. <source>AIDS Behav</source> <year>2016</year>; <volume>20</volume>(<issue>4</issue>): <fpage>811</fpage>&#x2013;<lpage>20</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>